Skip to main content
Contemporary Clinical Trials Communications logoLink to Contemporary Clinical Trials Communications
. 2024 Feb 1;38:101264. doi: 10.1016/j.conctc.2024.101264

Corrigendum to “Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: Rationale and protocol for single patient (n-of-1) multiple cross-over trials” [Contemp. Clin. Trials Commun. 36 (2023)/ DOI: 10.1016/j.conctc.2023.101233]

Bibiche den Hollander a,b,c, Marieke Rothuizen-Lindenschot d, Lisa Geertjens e,f, Frédéric M Vaz c,g,h,i, Marion M Brands a,b,c, Hoang Lan Le j,k, Agnies M van Eeghen a,b,l, Peter M van de Ven m, Martina C Cornel b,n, Bart AW Jacobs k,o, Hilgo Bruining b,e,f, Clara D van Karnebeek a,b,c,n,
PMCID: PMC10964043  PMID: 38533474

The authors regret the need for the following corrigendum:

In table 1, the amino acid change for the patient is listed incorrectly. It should be p.(Arg696Leu) instead of p.(Arg820Leu).

The authors would like to apologise for any inconvenience caused.


Articles from Contemporary Clinical Trials Communications are provided here courtesy of Elsevier

RESOURCES